- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07848373
Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%
A Clinical Evaluation of Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%
Dry Eye Disease is a multifaceted condition which has symptoms such as eye dryness, burning, and stinging sensation in the eyes. As well as clinical diagnosis such as a decreased ability to create tear film. Despite improvements in Contact Lenses (CL) DED still is responsible for a large percentage of CL dropouts due to discomfort. Thus, the purpose of this study is to determine if acoltremon 0.003% can improve the frequency and severity of DED symptoms in CL wearers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This 1 month 3 visit, single arm open label study aims to determine if acoltremon 0.003% can improve the frequency and severity of Dry Eye Disease (DED) symptoms in CL wearers. DED is a multifactorial condition that can cause stinging, burning sensation or dry eyes. It can also have clinically significant findings such as decreased tear production (aqueous-deficient DED) or increased tear evaporation (evaporative DED). Conditions like this often lead to discomfort, and thus individuals to drop out of wearing contact lenses. With nearly 20% of CL dropouts annually being due to discomfort.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Chris Lievens, OD, PhD
- Phone Number: 901-481-5699
- Email: clievens@sco.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
• Adult subjects who are ≥18 years of age.
- Best corrected CL visual acuity of 0.1 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes (Snellen equivalent 20/25).
- Willing to wear a new pair of CLs to the baseline study visit.
- Daily, soft, frequent replacement CL wearer (daily disposable, bi-weekly, or monthly CLs).
- An Eye Dryness VAS score of ≥40.
- CLDEQ-8 scores (CLDEQ-8 scores ≥12).
- A score of >7 dots on the Lexitas NEI staining scale (grade 1 in a single sector on the 5-sector scale).
- Habitual wearers of soft CLs for a minimum of 5 days per week for 6 hours or more per day during the month prior to enrollment.
- Willing to maintain habitual soft CL wear of a minimum of 5 days per week for 6 or more hours per day for the 1 month duration of the study.
- Habitual CLs have an acceptable fit (good centration, movement, and coverage
Exclusion Criteria:
- Any history of acoltremon 0.003% use.
- Are currently an overnight CL wearer.
- Are currently hard or scleral CL wearers.
- Have known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).
- Have a history of ocular surgery within the past 12 months.
- Have a history of viral eye disease that may confound study results.
- Have a history of severe ocular trauma, active ocular infection or inflammation.
- Have ever used isotretinoin-derivates (e.g., Accutane).
- Are currently taking ocular medications (including topical glaucoma medication) or plan to during the study.
- Have had a physical meibomian gland treatment withing 1 month of enrollment (iLux, Lipiflow, Radio Frequency and IPL with manual expressions, microblepharoexfoliation etc.).
- Have used a prescription DED medication in the last 1 month.
- Unwilling to agree to discontinue artificial tear use the day before enrollment and throughout the study.
- Have a condition or in a situation, which in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation.
- Are pregnant or breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: acoltremon 0.003%
participants will be provided with acoltremon 0.003% and instructed to use it twice a day. |
Acoltremon 0.003% (TRYPTYR; Alcon Laboratories; Fort Worth, TX, USA) was recently approved by the US Food and Drug Administration (FDA) as the first transient receptor potential melastatin (TRPM8) agonist for the treatment of DED. Acoltremon 0.003% is dosed twice a day |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Eye Dryness Score (VAS) at 4 weeks compared to baseline
Time Frame: 1 month
|
participants will be asked to evaluate their eye dryness using a VAS scale with higher numbers indicating greater comfort. |
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Eye Dryness Score (VAS) at 2 weeks compared to baseline
Time Frame: two weeks
|
participants will be asked to complete an eye dryness visual analog scale with higher numbers indicating greater comfort |
two weeks
|
|
CL End of day comfort VAS
Time Frame: 4 weeks
|
participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort |
4 weeks
|
|
CL End of day comfort VAS
Time Frame: 2 weeks
|
participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort |
2 weeks
|
|
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Time Frame: 1 month
|
participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort |
1 month
|
|
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Time Frame: 2 weeks
|
participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort |
2 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB000673-Acoltremon dry eye
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
An abstract describing the primary outcome will be submitted for ARVO 2027, and a manuscript on the same topic will be submitted to Contact Lens & Anterior Eye or similar publication. An abstract related to the Likert survey results will be submitted to Optometry's Meeting 2027
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.